trb_welcome.jpg

 

The mission of TRB Chemedica Group is to sell innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology. 

vismed.jpgTRB Chemedica S.A. reached agreement with River Plate Biotechnology, Inc. (a subsidiary of Lantibio, Inc.) and Alcon for a license to market, in the United States, a treatment for dry eye based on hyaluronic acid. The candidate product is currently in Phase III clinical studies.

vismed_gel_logo.gif

For a longer lasting relief

VISMED® gel is a preservative-free viscoelastic solution for sustained lubrication of the eyes in case of sensations of dryness, burning or ocular fatigue induced by environmental conditions, extended computer screen use, contact lens wear or by ophthalmological screening methods.

VISMED® gel is a patented hypotonic formulation that contains both 0.30% sodium hyaluronate, a natural polymer which is also present in the structures of human eyes, and most of the essential ions that are present in natural tears.

VISMED® gel is available in boxes of 20 (or 60) reclosable single dose units of 0.45 ml.

 

vismed_gel_box01.jpg

pdf VISMED® gel leaflet
trb_lock.gif Doctor information
Distributors
trb_contact.gifContacts

 
 
  • English